Introduction
An excess of leukaemia has been observed after treatment of a variety of adult' 6 and childhood cancers.78 Case-control studies have identified specific groups of cytotoxic drugs that are associated with an increased risk of secondary leukaemias9''2; these and other studies have particularly identified alkylating agents as being associated with an increased risk of secondary leukaemia after adult and childhood cancers. Radiation exposure is undoubtedly involved in some leukaemias. 13 There have also been suggestions that the epipodophyllotoxins may be related to an increased risk of subsequent leukaemias.112' We report the results of a population based cohort study and a casecontrol study carried out (a) to estimate the absolute risk of secondary leukaemia after childhood cancer in Britain, and (b) to determine those aspects oftreatment related to an increased relative risk of secondary leukaemia.
Methods PATHOLOGICAL CONFIRMATION OF NEOPLASMS
Each case included in the case-control study had representative slides of both the first and second neoplasms centrally reviewed and confirmed by a paediatric histopathologist (HBM). In addition, each possible occurrence of leukaemia after an initial leukaemia or non-Hodgkin's lymphoma was centrally reviewed by a haematologist (JMC). For each control we obtained the definitive pathology report(s) confirming the diagnosis concerned. For those patients included in the cohort study who did not develop a secondary leukaemia almost all diagnoses were histologically verified except for 4% of the leukaemias, 9% of the central nervous system tumours, and 8% of the retinoblastomas, which were based on blood counts, radiology or scans, and observation under anaesthesia respectively. COHORT 
STUDY
From the population based National Register of Childhood Tumours maintained by the Childhood Cancer Research Group we identified children aged under 15 years who were diagnosed with cancer between 1962 and 1983 while resident in Britain and who subsequently survived at least one year. Entry to the study occurred one year after diagnosis, and patients exited when the first of one of the following occurred: a secondary leukaemia was diagnosed; the BMJ VOLUME 304 11 APRIL 1992 patient died; the date of last follow up was reached. A specifically designed follow up study was carried out by writing to the general practitioners of all eligible patients who were not known to have died asking about the possible development of a second primary neoplasm. To ensure that our ascertainment of secondary leukaemia was complete all patients not known to have died were flagged at the NHS central register, which should ensure the automatic notification of any deaths or cancers registered for flagged patients. For patients known to have died we routinely obtained the general practitioners' notes, which were inspected for any evidence that a secondary leukaemia had been diagnosed. In addition, through our close links with the United Kingdom Children's Cancer Study Group consultants at the main centres treating childhood cancer in Britain directly informed us of second primary neoplasms diagnosed in their patients.
For patients who were alive and not diagnosed with secondary leukaemia the study end date was the date the general practitioner completed the questionnaire indicating that the patient was alive and had never been diagnosed with a secondary leukaemia. In our national register of secondary neoplasms after childhood cancer we do not allow for the occurrence of secondary lymphoblastic leukaemia after either an initial lymphoblastic leukaemia or a non-Hodgkin's lymphoma. Therefore, to ensure that observed and expected numbers were comparable we excluded lymphoblastic leukaemia from the population rates used for calculating expected numbers of leukaemias after these two initial childhood neoplasms. Moreover, because the few secondary leukaemias observed within the cohort were intensively followed up there were few with an unspecified cell type. In contrast, the general population rates of leukaemia include a substantial fraction of leukaemias of unspecified cell type. Therefore, we distributed the unspecified leukaemias occurring in the general population between the specified cell types in proportion to the relative frequency of the specified cell types. In this way we attempted to produce estimates of relative risk that were as free of bias as possible. assumption that all agents within a particular group share an equal leukaemogenic potency for a specified amount of drug given per unit of surface area. For ease of communication we term these two methods of measuring exposure to particular groups of drugs the "SCORE" and "EQUIVALENT mg/m2" methods respectively.
Results Table I gives a cross tabulation of the types of initial neoplasms and types of secondary leukaemia observed in the cohort and case-control studies. Twenty six secondary leukaemias were included in the casecontrol study, including the four patients whose initial childhood neoplasm was diagnosed before 1962 and excluded from the cohort study. Only relatively recently have reliable techniques become available to distinguish different types of leukaemia within an individual patient, and this is reflected by only one of the patients developing two distinct leukaemias being diagnosed with the first leukaemia before 1980.
COHORT STUDY Among 16422 patients who survived at least one year after being diagnosed with a childhood neoplasm in Britain between 1962 and 1983 inclusive, 22 secondary leukaemias were observed, ofwhich 16 were acute myeloid in type. The interval between diagnosis of the initial childhood neoplasm and the subsequent leukaemia was consistently under six years for patients in the cohort study. For the entire cohort 2-72 secondary leukaemias were expected, yielding a relative risk of 8 (table II) . Table II shows that the absolute risk of secondary leukaemia was greatest after nonHodgkin's lymphomas, with an estimated cumulative risk of 1-4% at five years from one year survival. This corresponds to 112 times the expected number of leukaemias. The mean follow up period beyond one year survival for the entire cohort was 7-7 years.
Table II also shows the variation in the relative risks of subsequent myeloid or monocytic leukaemias after different initial childhood neoplasms. Seventeen acute myeloid or monocytic leukaemias were observed, which was 17 times the number expected. The relative risk of myeloid or monocytic leukaemia was greatest after non-Hodgkin's lymphomas, at 129 times the number expected. The treatment information available on the generality of the cohort was poor compared with that collected within the case-control study; furthermore, it was incomplete, in that there were 4338 patients (26% of the cohort) for whom whether they had received radiotherapy or chemotherapy, or both, was unknown. Therefore, it was considered unwise to attempt to estimate the risk of secondary leukaemia for separate treatment groups. Table III gives the variation in the risk of a subsequent leukaemia generally, and myeloid or monocytic leukaemia specifically, in relation to the decade (1962-9, 1970-9, 1980-3) in which the initial childhood neoplasm was first treated. There was clear evidence of an increased risk of subsequent leukaemias among those treated more recently. The cumulative risks of secondary leukaemia after non-Hodgkin's lymphomas five years from entry after treatment in 1962-9, 1970-9, and 1980-3 were 0%, 0 5%, and 4% respectively. Although these associations were strong and undoubtedly largely real, an element of artefact was involved. As mentioned above, only relatively recently have the techniques been available to identify the occurrence of secondary leukaemia after initial leukaemia. Also it is possible that, in the absence of expert knowledge of paediatric histopathology, secondary non-lymphoid leukaemia after nonHodgkin's lymphoma was sometimes in the past ascribed to a progression of the original disease.
CASE-CONTROL STUDY
There were 26 cases included, and we attempted to select four controls per case. In fact, we were unable to select eight controls because even after some relaxation Although it is apparent from table IV that radiotherapy was associated with an increased risk of subsequent leukaemia, further insight may be obtained by subdividing the study population according to dose of radiation averaged over the patients' active bone marrow. The results of this are given in table V. There was evidence ofa trend in the relative risk ofsubsequent leukaemia with increasing average dose of radiation received by the patients' active bone marrow. However, the estimates ofrelative risk associated with the specific levels of exposure were subject to wide 95% confidence intervals.
Chemotherapy was given to 69% and 55% of cases and controls respectively. Almost all of those patients receiving chemotherapy had multiple drugs: 94% and 79% of cases and controls respectively who received chemotherapy were given at least four different cytotoxic agents. Furthermore, as there was a wide spectrum of initial childhood neoplasms among the cases, and therefore among controls, the types and combinations of drugs used were very heterogeneous. However, the cytotoxic drugs given were mainly of the There was no evidence of any statistically significant non-linear variation in the relative risk of subsequent leukaemia with exposure to any of the aspects of treatment concerned, irrespective of the method of quantifying exposure to particular groups of drugs. Therefore, in all subsequent analyses we fitted only a single parameter corresponding to a linear trend with each particular aspect of treatment. Table VI shows that the evidence of a trend in the relative risk of leukaemia with increasing exposure to alkylating agents was not quite significant after controlling for exposure to radiation and epipodophyllotoxins. However, a one tailed test, half the p value given in table VI, was significant (p= 0-044) when quantifying exposure using scores and almost significant (p=0 086) when using the equivalent mg/m2 method. Table V shows that the trend in the relative risk of secondary leukaemia with increased averaged active bone marrow exposure to radiation remained after controlling for exposure to both epipodophyllotoxins and alkylating agents. Similarly, in table VII there is evidence that the trend in the relative risk of secondary leukaemia with increased exposure to epipodophyllotoxins remained after controlling for exposure to both radiation and alkylating agents.
The results given above, concerning the four elements of treatments that were each separately related to an increased relative risk of subsequent BMJ VOLUME 304 
Discussion
There was strong evidence from our data that the relative risk of secondary leukaemia increases with increasing dose of epipodophyllotoxins and with increasing dose of radiation averaged over the active bone marrow of patients as a result of radiotherapy. There was also evidence of an increase in the relative risk of second leukaemia with increasing dose of alkylating agents.
There have been previous suggestions that the epipodophyllotoxins might be related to an increased risk of subsequent leukaemia. In particular, evidence has emerged from the comparison of two series of children treated for acute lymphoblastic leukaemia.
In one series, from St Jude's Children's Research Hospital,'6 at six years from diagnosis the cumulative risks of acute myeloid leukaemia were 19-1% and 2 9% among patients with and without a T cell immunophenotype respectively. Most patients received an epipodophyllotoxin, including all those with T cell acute lymphoblastic leukaemia and, most notably, 12 of the 13 patients who developed secondary acute myeloid leukaemia. A preliminary communication from the other series,'7 arising from the Dana Farber Cancer Institute, the Children's Hospital in Boston, and the University of Rochester Cancer Centre, based on a similar number of children followed up for a similar interval reported only two patients developing acute myeloid leukaemia, only one case diagnosed in a patient with a previous T cell immunophenotype. Epipodophyllotoxins were never used to treat acute lymphoblastic leukaemia in this latter series.
There is also evidence of a relation between the administration ofepipodophyllotoxins and an increased risk of acute non-lymphoid leukaemia after non-small cell carcinoma of the lung,'4 neuroblastoma,'5 solid tumours of childhood,8 19 and germ cell tumours.Y' A recent review21 identified 37 patients who had developed acute non-lymphocytic leukaemia after epipodophyllotoxins. An observation made in relation to a substantial number of these apparently epipodophyllotoxin related acute non-lymphoid leukaemias was that there seemed to be an associated chromosomal abnormality involving 1lq23,'1'6'82021 31 suggesting the possibility of a specific mechanism of induction. The cytogenetic abnormalities commonly associated with secondary acute non-lymphoid leukaemia involve chromosomes 5 and 7.3235 A remaining uncertainty in interpreting the association between the relative risk ofsubsequent leukaemia and degree of exposure to epipodophyllotoxins as being causal in our data relates to other treatment received by the patients given epipodophyllotoxins and developing a secondary leukaemia. As a result of there being relatively few patients with secondary leukaemia in our study, and considerable heterogeneity of drug combinations used, we were unable to examine the variation in relative risk of secondary leukaemia and the dose ofindividual drugs. Therefore, it is conceivable that there was some other important aspect of the cocktail of drugs and radiotherapy received by these patients that affected the risk of secondary leukaemia.
Each patient developing leukaemia after an epipodophyllotoxin also recieved at least one alkylating agent and most received at least two. For example, cyclophosphamide and lomustine were received by nine and six, respectively, of the 10 patients who developed leukaemia after administration of an epipodophyllotoxin. Lomustine, an alkylating agent (nitrosourea), is a potent leukaemogen.436 Cyclophosphamide, another alkylating agent, has long been associated with secondary leukaemia, although it seems to be less leukaemogenic than most other alkylating agents." [37] [38] [39] Additionally, radiotherapy was used to treat the original childhood cancer in eight of these 10 patients.
However, despite these uncertainties, given the strong dose-response from our data, the support ofassociations from other studies linking the epipodophyllotoxins and secondary leukaemia, and the occurrence of balanced translocations involving 1 lq23 corresponding to a third of the secondary leukaemias for which there were successful chromosome studies after an epipodophyllotoxin, the cumulative evidence favours interpreting our data as indicating a dominant effect of either the epipodophyllotoxins acting alone or epipodophyllotoxins acting together with alkylating agents or radiation in the development of secondary leukaemia.
ABSOLUTE RISK OF SECONDARY LEUKAEMIA Our cohort study indicates that the absolute risk of secondary leukaemia after an initial childhood neoplasm is low except after non-Hodgkin's lymphoma. Pui et all' ' have reported the low risk of myeloid neoplasia after solid tumours in childhood, and the only notable discrepancy between their series and ours is the relatively high risk of secondary leukaemia after non-Hodgkin's lymphomas treated in Britain in the early 1980s. The considerable risk of second malignancy after treatment of non-Hodgkin's lymphoma and T cell leukaemia with the United Kingdom Children's Cancer Study Group regimens during this period has been reported.' This increased risk is probably explained to a large extent by the epipodophyllotoxins that were given in association with alkylating agents and radiotherapy to treat nonHodgkin's lymphomas in Britain during this period. Under the United Kingdom Children's Cancer Study Group's clinical trial protocol used to treat patients with non-Hodgkin's lymphomas between 1977 and 19834' a patient who did not relapse might have received a total dose of teniposide of between 800 and 900mg/m2. Table VII shows that this range of doses is associated with a risk of secondary leukaemia about 12 times that among patients not exposed to epipodophyllotoxins.
The only epipodophyllotoxin used to treat all but one of the 10 patients developing secondary leukaemia after an epipodophyllotoxin was teniposide; one patient developed secondary leukaemia after etoposide. Laboratory work has indicated that although teniposide and etoposide have similar kinetics for DNA break formation and repair and similar relations between DNA breakage and cytotoxicity, teniposide is around 10 times more potent than etoposide in causing DNA damage in vitro and in ViVo.42 43 In our data the association between exposure to alkylating agents and the relative risk of secondary leukaemia was of only borderline significance after controlling for exposure to radiation and epipodophyllotoxins. However, this should not be interpreted as indicating that alkylating agents were not involved in the development of secondary leukaemia. It seems likely that this resulted from the relatively small number of cases in our study and an association with exposure to alkylating agents in aggregate, which was weaker than that with exposure to epipodophyllotoxins in aggregate. Cyclophosphamide was by far the most common alkylating agent used to treat patients in our study and there has been previous evidence suggesting that this is one of the weaker leukaemogens among the alkylating agents. 10 37-39 In the Late Effects Study Group case-control study of leukaemia after childhood cancer a very different pattern of treatment with alkylating agents was observed from that seen in our study, procarbazine and nitrogen mustard being the most commonly used alkylating agents in both cases and controls. ' 12 The Late Effects Study Group study found no evidence ofan association between the dose ofradiation averaged over patient's active bone marrow and the relative risk of leukaemia. This apparent discrepancy with our study may have arisen as a result of the method of estimating the average active bone marrow dose of radiation received. Although a comparable estimation method was used in both studies, it is possible that because of the substantially different mix of first cancers that preceded leukaemia in the two studies, and the differing therapeutic practices prevailing between the studies, that the radiotherapy fields used for patients included in our study may have resulted in a lower average exposure of larger volumes of bone marrow than the fields used in the Late Effects Study Group study. If so, the leukaemia rate might have been higher in our study because for a specified dose averaged over a patient's entire bone marrow less killing of cells might occur and therefore more cells would be susceptible to leukaemogenic transformation. This hypothesis has been suggested as a possible explanation of the higher relative risk of leukaemia after Hodgkin's disease9 than after cervical cancer."
TOWARDS AN ASSESSMENT OF EPIPODOPHYLLOTOXINS
The epipodophyllotoxins were initially used by British paediatric oncologists in the late 1970s. Although teniposide has not been used much in Britain, it is used to treat substantial numbers of adults with cancer within mainland Europe-for example, in the treatment of lymphomas. Etoposide is used extensively within Britain in the treatment of cancer in adults and was initially introduced for the treatment of non-Hodgkin's lymphoma and acute leukaemia. It is of concern that our findings may apply to the treatment of adults with cancer and therefore there is a need for a similar study relating to adult patients. It would be prudent to use epipodophyllotoxins-particularly given with alkylating agents and radiotherapy-with caution in the treatment of childhood cancer, and if there exists an alternative regimen producing similar survival prospects but less risk of second neoplasms then this should be adopted. The results of this study should not be viewed too pessimistically since the few secondary leukaemias observed need to be considered against the thousands ofpatients who have experienced improved survival or have been cured as a result of using modern treatment methods.
It is not possible at present to give a detailed overall assessment of the clinical value of epipodophyllotoxins because there is insufficient information. This is because these agents are relatively new, and also they are usually used in combination with other cytotoxic agents with consequent difficulties in identifying the effects of individual drugs. For each cancer for which epipodophyllotoxins are proposed or used as a part of treatment the following questions need to be addressed:
(1) How many extra patients diagnosed will survive with the use of epipodophyllotoxins within five (or 10) years compared with the best alternative regimen or protocol? (2) How many extra secondary malignant neoplasms will develop during the corresponding period? (3) Does comparison of (1) and (2) indicate there is a net advantage or disadvantage associated with the use of epipodophyllotoxins? This simple formulation ignores other possible untoward effects of treatment that may also need to be taken into account. The most satisfactory source for such information is undoubtedly randomised clinical trials. As mentioned above, the United Kingdom Children's Cancer Study Group non-Hodgkin's lymphoma and T cell leukaemia/lymphoma clinical trial treatment protocols which were used to treat patients diagnosed in the United Kingdom between mid-1977 and mid-1983 resulted in 7-8% of patients developing a second malignant neoplasm by seven years from diagnosis. The protocols have subsequently been modified, and in particular adjuvant radiotherapy has been discontinued4 45 and teniposide replaced by etoposide. It is important that results from these trials are used to monitor changes in survival and the risk of secondary malignancy that are associated with the change of protocol.
With regard to conclusions to be drawn from the present study three aspects of the data should be emphasised. Firstly, the relation between exposure to epipodophyllotoxins and secondary leukaemia revealed evidence of a striking dose dependence in risk, and therefore whether to include epipodophyllotoxins as part of a treatment protocol might depend on whether it was proposed to give relatively high or low doses. Secondly, our data relate almost exclusively to teniposide, and the risk of secondary leukaemia after etoposide may be different. Thirdly, the majority of patients developing leukaemia after receiving an epipodophyllotoxin also received at least two alkylating agents and radiotherapy; consequently the risk of secondary leukaemia may be different after an epipodophyllotoxin given as part of a different treatment regimen.
FURTHER STUDY: INTERNATIONAL COLLABORATION
It is clear that there is a need to amalgamate the data from small case-control studies such as ours and that carried out by the Late Effects Study Group. In fact, our study was designed so that it would be possible easily to amalgamate the data from these two studies into one large data set that could be analysed afresh with the possibility ofgaining new insights. In addition, given the rarity of second leukaemia within particular countries there is a clear need for wider international collaboration in combining the results from as many countries as could provide data. Anyone or any institution interested in collaborating in such an international collaborative case-control study of secondary leukaemia after childhood neoplasms is invited to write to MMH.
